News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

01/23/2022 | 12:19pm EDT

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Dyne and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On January 18, 2022, Dyne issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy amenable to skipping exon 51.”  Dyne reported that it “received a clinical hold letter from the FDA on Friday, January 14, 2022 requesting additional clinical and non-clinical information for DYNE-251” and that “the Company expects to submit to the FDA its response with data from existing and ongoing studies in the second quarter of 2022, and if satisfactory to the FDA, to be dosing patients in a Phase 1/2 multiple ascending dose clinical trial of DYNE-251 by mid-2022 in accordance with its current guidance.” 

On this news, Dyne’s stock price fell $1.17 per share, or 12.59%, to close at $8.12 per share on January 18, 2022.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980



© GlobeNewswire 2022
Latest news "Companies"
05:59pSsr mining announces voting results from 2022 annual meeting of shareholders
PR
05:58pSsr mining announces voting results from 2022 annual meeting of shareholders
AQ
05:58pZeuus, inc. - 10-k/a - management's discussion and analysis of financial condition and result of operations
AQ
05:57pLCNB CORP : Other Events (form 8-K)
AQ
05:57pUNUM GROUP : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Shareholder Director Nominations (form 8-K)
AQ
05:57pSTATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:57pRivian Founder and CEO RJ Scaringe to Participate in Bernstein's 38th Annual Strategic Decisions Conference
BU
05:55pMASTEC INC : Financial Statements and Exhibits (form 8-K)
AQ
05:55pTRAVELERS COMPANIES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:55pMSP RECOVERY, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Latest news "Companies"